ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0934

Warfarin Use and Risk of Knee and Hip Replacements

Priyanka Ballal1, Christine Peloquin1, Cindy Boer2 and Tuhina Neogi1, 1Boston University School of Medicine, Boston, MA, 2Erasmus Medical Center, Rotterdam, Netherlands

Meeting: ACR Convergence 2020

Keywords: nutrition, Osteoarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 7, 2020

Title: Plenary Session II (0934–0939)

Session Type: Plenary Session

Session Time: 11:30AM-1:00PM

Background/Purpose: Vitamin K is an essential co-factor in the post-translational gamma-carboxylation of glutamic acid to form gamma-carboxy-glutamic acid (Gla) residues. This confers functionality to vitamin K-dependent proteins including those in bone and cartilage that play an important role in regulating mineralization. Low vitamin K can lead to under-carboxylation of Gla proteins and thus their dysfunction. Vitamin K deficiency has been associated with OA, and a randomized trial of vitamin K supplementation demonstrated trends towards less OA progression. Studies to date have not evaluated whether vitamin K antagonism with warfarin can be detrimental to OA. We therefore evaluated the relation of warfarin to risk of knee and hip replacements as a reflection of end-stage OA. 

Methods: We conducted a nested case-control study using The Health Improvement Network, a general practitioner (GP)-based electronic medical records database from the UK that is representative of the general population. To minimize confounding by indication, we limited our study sample to adults (aged 40-89) with atrial fibrillation, as this diagnosis warrants therapy with anticoagulation. Additionally, we compared warfarin, a vitamin K antagonist, with direct oral anticoagulants (DOAC), which are not vitamin K antagonists. Because DOACs were first marketed in the UK in 2008, we limited our study to those who had been enrolled for ≥1 year with a GP between 2009 and 2018. We excluded individuals with knee or hip replacement (KR/HR) prior to 2014, severe co-morbidities that would limit surgery, those with warfarin or DOAC use within 1 year prior to our study period, and those who used both drugs during study period. We identified cases as those with KR or HR between 2014-2018, with surgery date being the index date for cases. Each case was matched with up to 4 controls by age and gender. We defined warfarin and DOAC use as having ≥1 prescription after study entry and within 1 year prior to the index date. We assessed the relation of warfarin compared with DOAC use to risk of KR or HR using conditional logistic regression, adjusting for potential confounders.

Results: We identified 913 subjects with KR or HR (cases) who were age and gender-matched 4:1 with 3652 controls (mean age 74, 46% female). Of the 913 cases, 64.9% were warfarin users while 35.1% were DOAC users; in contrast, of the 3652 controls, 56.3% were warfarin users while 43.6% were DOAC users. With adjustment for potential confounders, warfarin users had 1.57 times higher odds of KR or HR than DOAC users (Adjusted OR 1.57, 95% CI (1.30-1.89)) (Table). When matched by practice ID to account for practice variation, we found a slightly diminished but significant association (Adjusted OR 1.25, 95% CI (1.03-1.52)). There was increasing risk of KR or HR with duration of warfarin vs. DOAC exposure (Figure).

Conclusion: Warfarin use, a vitamin K antagonist, was associated with significantly greater risk of KR or HR (an indicator for end-stage knee OA) than DOAC use, with risk increasing with duration of use. These data add further support to the importance of adequate vitamin K and its dependent proteins in limiting progression of OA and raises the consideration of using DOACs over warfarin when indicated in those with or at risk of OA.

Table: Relation of Warfarin versus DOAC use to Risk of Knee or Hip Replacement

Figure: Relation of Duration of Anti coagulation use (warfarin vs. DOAC) to Risk of KR or HR


Disclosure: P. Ballal, None; C. Peloquin, None; C. Boer, None; T. Neogi, Lilly, 1, EMD Merck Serono, 1, Novartis, 1, Regeneron, 1, Pfizer/Lilly, 1.

To cite this abstract in AMA style:

Ballal P, Peloquin C, Boer C, Neogi T. Warfarin Use and Risk of Knee and Hip Replacements [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/warfarin-use-and-risk-of-knee-and-hip-replacements/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/warfarin-use-and-risk-of-knee-and-hip-replacements/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology